Background: The management of severe mental illness (SMI) with long-term antipsychotic medications presents a significant clinical challenge due to the high risk of iatrogenic metabolic syndrome (MetS). This cluster of cardiometabolic risk factors substantially increases morbidity and mortality in an already vulnerable population. Systematic monitoring is paramount, yet its implementation in real-world clinical settings remains consistently suboptimal.[1][2] Objectives: This study aimed to conduct a comprehensive evaluation of metabolic monitoring practices in a real-world clinical setting. The primary objectives were: 1) to assess the completeness of documentation for key clinical parameters, with a particular focus on blood pressure and glycemic status, in MetS screening charts for patients on long-term antipsychotic therapy; and 2) to analyze the six-month trajectory of these metabolic parameters to identify trends and quantify the burden of MetS components. Methods: A retrospective, observational cohort study was conducted at a tertiary care Psychiatry Outpatient Department (OPD) in North India. The medical records of 100 adult patients receiving continuous antipsychotic treatment for over one year were reviewed. Key metabolic parameters, including waist circumference, Body Mass Index (BMI), blood pressure, fasting plasma glucose, HDL cholesterol, and triglycerides, were extracted at baseline, three-month, and six-month intervals according to International Diabetes Federation (IDF) 2006 criteria. Data completeness was calculated, and temporal trends were analyzed using descriptive statistics and paired-samples t-tests.[3] Results: The cohort had a mean age of 40.5 (±13.5) years, with 53% being male, consistent with North Indian psychiatric populations. Clozapine was the most frequently prescribed agent (29%), followed by other high-metabolic-risk antipsychotics. Overall documentation completeness was high (96.7%), but significant gaps were identified for blood pressure and fasting glucose, both of which had a consistent 10% rate of missing data, reflecting systematic monitoring deficiencies reported globally. Over the six-month observation period, several parameters worsened significantly: mean BMI increased from 27.1 to 29.0 kg/m² (p=0.002), mean triglycerides rose from 163.1 to 173.1 mg/dL (p=0.021), and mean systolic blood pressure escalated from 134.9 to 142.0 mmHg (p<0.001). At the six-month endpoint, the prevalence of individual MetS components was alarmingly high: central obesity (77%), elevated triglycerides (79%), low HDL (71%), elevated blood pressure (94%), and hyperglycemia (51%). These rates substantially exceed those reported in the general Indian population (30-34%) and align with the upper range of international antipsychotic studies.[4][2][5][6][7][8][9][10][11][12] Conclusions: Patients on long-term antipsychotics in this North Indian cohort exhibit a profound and worsening burden of metabolic abnormalities. Critical deficiencies in the documentation of blood pressure and glucose monitoring undermine effective preventative care. These findings underscore an urgent need for the implementation of standardized, multidisciplinary monitoring protocols, enhanced staff training, and the integration of physical health management into routine psychiatric practice to mitigate the severe cardiometabolic risks in this population.[13][2][9][14]

Severe mental illnesses (SMI), such as schizophrenia and bipolar disorder, are chronic conditions that impose a substantial global health burden. The advent of second-generation antipsychotics (SGAs) revolutionized the management of these disorders, offering improved control of psychotic symptoms and a lower risk of extrapyramidal side effects compared to their predecessors. However, this therapeutic advancement has been accompanied by a significant iatrogenic cost: a high propensity for inducing metabolic dysregulation. Pharmacological mechanisms, including potent antagonism of histamine H1 and serotonin 5-HT2C receptors, are strongly implicated in promoting weight gain and altering glucose and lipid homeostasis.[5][15][7][1] This drug-induced metabolic dysfunction frequently culminates in the development of metabolic syndrome (MetS), a constellation of risk factors including central obesity, dyslipidemia, hypertension, and insulin resistance. Individuals with SMI treated with antipsychotics have a two- to three-fold higher prevalence of MetS compared to the general population, which contributes to a staggering 15- to 20-year reduction in life expectancy, primarily due to cardiovascular disease.[6][1][3] Recent meta-analyses demonstrate that the prevalence of metabolic syndrome among psychiatric patients on antipsychotic medications ranges from 22% in African populations to 37-63% in developed countries. Notably, clozapine and olanzapine consistently demonstrate the most severe metabolic adverse effect profiles, with up to 58% of clozapine-treated patients meeting criteria for metabolic syndrome.[7][16][17][4][5][6] Recognizing this crisis, numerous international bodies have published guidelines recommending routine and comprehensive metabolic monitoring for all patients receiving antipsychotic therapy. Despite these clear recommendations, a significant gap persists between guidelines and real-world clinical practice. Studies from various global settings consistently report suboptimal rates of screening and documentation, particularly for blood pressure and glycemic indices. A recent systematic review found that metabolic monitoring rates were "generally inadequate" except for body weight (75.9%) and blood pressure (75.2%). This implementation failure is often exacerbated in resource-limited settings like India, where high patient loads, fragmented healthcare systems, and persistent stigma surrounding mental illness create formidable barriers to integrated care.[2][15][9][14][18] This study, therefore, sought to illuminate the state of metabolic monitoring and the prevalence of MetS components within a typical North Indian psychiatric outpatient setting, providing crucial regional data and identifying targets for quality improvement.

Patient Characteristics The demographic and clinical profile of the cohort is detailed in Table 1. The 100 patients had a mean age of 40.5 years, with a fairly balanced gender distribution consistent with other North Indian psychiatric populations.[20][12] Table 1: Demographic and Clinical Characteristics Characteristic Value Reference Notes Sample Size (n) 100 Study cohort Mean Age (years) ± SD 40.5 ± 13.5 Consistent with North Indian psychiatric populations[12] Age Range (years) 18–64 Adult population as per inclusion criteria Male 53 (53.0%) Gender distribution similar to other Indian psychiatric studies[20][12] Female 47 (47.0%) Gender distribution similar to other Indian psychiatric studies[20][12] The prescription patterns (Table 2) revealed that SGAs with a high metabolic risk profile were commonly used. Clozapine was the most prescribed agent, followed by quetiapine and olanzapine, which collectively accounted for 67% of the prescriptions in this cohort, reflecting the known preference for high-efficacy agents despite their metabolic burden.[15][17][5][7] Table 2: Antipsychotic Medication Distribution with Metabolic Risk Profiles Antipsychotic Medication Number of Patients (n) Percentage (%) Metabolic Risk Profile Clozapine 29 29.0% Very High[5][7] Quetiapine 23 23.0% High[15] Risperidone 17 17.0% Moderate[15] Aripiprazole 16 16.0% Low[17] Olanzapine 15 15.0% Very High[5][15][7] Total 100 100.0% - Trends in Metabolic Parameters The six-month longitudinal data presented in Table 3 reveal a clear and statistically significant deterioration in the metabolic health of the cohort, consistent with patterns observed in longitudinal antipsychotic studies. The mean BMI increased from an overweight classification to one bordering on Class I obesity. Similarly, mean triglyceride levels and systolic blood pressure, both already elevated at baseline, worsened significantly over the follow-up period.[8] Table 3: Temporal Changes in Metabolic Parameters Parameter Baseline Mean ± SD 3 Months Mean ± SD 6 Months Mean ± SD P-value (Baseline vs 6M) Clinical Interpretation Waist Circumference (cm) 95.5 ± 10.5 97.0 ± 9.2 97.3 ± 9.5 0.213 Non-significant trend BMI (kg/m²) 27.1 ± 3.7 27.8 ± 3.9 29.0 ± 4.1 0.002* Significant weight gain[8] Fasting Glucose (mg/dL) 97.5 ± 15.8 96.4 ± 18.0 101.7 ± 18.8 0.213 Non-significant elevation HDL Cholesterol (mg/dL) 41.1 ± 7.2 40.7 ± 7.7 41.2 ± 9.1 0.936 Stable low HDL levels Triglycerides (mg/dL) 163.1 ± 29.3 167.5 ± 32.0 173.1 ± 30.1 0.021* Significant dyslipidemia worsening[8] Systolic BP (mmHg) 134.9 ± 12.5 136.7 ± 13.1 142.0 ± 14.2 <0.001** Highly significant hypertension progression[8] Diastolic BP (mmHg) 87.0 ± 8.2 89.1 ± 8.8 90.8 ± 9.5 0.067 Trending toward significance *p<0.05, **p<0.01, ***p<0.001 (paired t-test for baseline vs 6-month comparison) Prevalence of Metabolic Syndrome Components The cross-sectional analysis at the six-month endpoint (Table 4) painted a stark picture of the metabolic burden, substantially exceeding both general Indian population rates and many international antipsychotic studies. An overwhelming majority of patients met the criteria for at least one MetS component. Elevated blood pressure was nearly universal among those assessed (94.4%), representing a critical finding given that blood pressure monitoring had the poorest documentation compliance.[10][11][4][2][6][9] Table 4: Metabolic Syndrome Component Prevalence with Comparative Analysis MetS Component (IDF Criteria) Study Population n (%) General Indian Population (%)[10][11] Other Antipsychotic Studies (%)[4][21][6] Elevated BP (≥130/85 mmHg) 85/90 (94.4%) 23-29% 41.9% Elevated Triglycerides (≥150 mg/dL) 79/100 (79.0%) 27-54% 44.1% Central Obesity (M≥90cm, F≥80cm) 77/100 (77.0%) 31-52% 51.9% Low HDL (M<40, F<50 mg/dL) 71/100 (71.0%) 65-81% 48.1% Elevated Glucose (≥100 mg/dL) 46/90 (51.1%) 26-35% 35.9% Full MetS (≥3 components) Est. 70-80% 30-34% 22-38%

This study provides critical real-world evidence confirming the profound metabolic risk faced by patients on long-term antipsychotic therapy in a North Indian setting. The principal findings are threefold: the prevalence of individual MetS components is exceptionally high, key metabolic parameters demonstrate a significant worsening over a short six-month period, and critical gaps persist in the routine monitoring of blood pressure and glucose.[2][9] Comparison with Prior Literature The prevalence rates of MetS components in our cohort are substantially higher than the pooled prevalence of full MetS (typically 22-38%) reported in large-scale meta-analyses. Recent African studies report a pooled prevalence of 22%, while developed countries show rates of 37-63%. Our estimated prevalence of 70-80% full MetS exceeds these ranges significantly. Several factors may contribute to this discrepancy. First, there is evidence of a greater genetic predisposition to insulin resistance and central obesity in South Asian populations, with metabolic syndrome prevalence ranging from 30-34% in the general Indian population. Second, our study's inclusion of patients on high-metabolic-risk agents like clozapine (29%) and olanzapine (15%) likely enriched the sample with individuals more susceptible to these side effects. Recent network meta-analyses confirm that clozapine and olanzapine rank as the worst for metabolic-related adverse effects. Finally, lifestyle factors such as diet and physical activity, which were not measured in this study, may also play a significant role.[16][17][11][22][4][5][6][7][10] The progressive worsening of BMI, triglycerides, and blood pressure aligns with longitudinal studies that demonstrate the cumulative nature of antipsychotic-induced metabolic harm. Our finding of significant BMI increase (27.1 to 29.0 kg/m²) over six months is particularly concerning, representing progression from overweight to Class I obesity.[8] Clinical Implications and Barriers to Care The most concerning finding is the systematic failure to document blood pressure and fasting glucose for 10% of patients. This represents a critical breakdown in the care cascade that mirrors global patterns. Such omissions are not merely clerical errors; they signify missed opportunities for early detection, intervention, and prevention of catastrophic cardiovascular events. This "clinical inertia" is a well-documented phenomenon in mental healthcare, often stemming from a historical bifurcation of mental and physical health services.[13][9][14][2] Recent quality improvement studies demonstrate that institutional interventions can significantly improve metabolic monitoring rates, with odds ratios of 6.90 for glucose monitoring, 5.39 for lipid monitoring, and 4.81 for blood pressure monitoring. In a busy OPD setting, barriers such as time constraints, lack of readily available equipment (e.g., glucometers), insufficient staff training in physical health monitoring, and a primary focus on psychiatric symptoms can lead to the neglect of metabolic screening.[9][14][13][2] Regional Context and Global Implications Our findings from North India contribute to the growing body of evidence documenting the global burden of antipsychotic-induced metabolic syndrome. Previous North Indian studies have reported MetS prevalence ranging from 34.74% to 37.8% in psychiatric inpatients, which, while still elevated, are lower than our outpatient findings. This difference may reflect selection bias, as outpatients may have longer exposure to antipsychotics and different medication profiles.[12][20] The South Asian population shows particular vulnerability to metabolic syndrome, with recent community studies from eastern India reporting prevalence rates of 31.4-33.5% in the general population. Our findings of nearly universal elevated blood pressure (94.4%) and high rates of central obesity (77%) and dyslipidemia (79% elevated triglycerides, 71% low HDL) substantially exceed these population norms, underscoring the additional metabolic burden imposed by antipsychotic treatment. Limitations This study has several limitations inherent to its design. The retrospective nature prevents the establishment of causality and relies on the accuracy of existing clinical records. The sample was drawn from a single tertiary care center, which may limit the generalizability of the findings to primary care or other regions. We did not collect data on potential confounding variables, including diet, physical activity levels, smoking status, or family history of metabolic disease, which are known to influence metabolic outcomes. Furthermore, the 6-month follow-up period, while demonstrating rapid decline, may not capture the full long-term trajectory of metabolic risk. Finally, the study was underpowered to perform subgroup analyses comparing the metabolic effects of different antipsychotic agents, though our descriptive findings align with established metabolic risk hierarchies.

In this North Indian cohort of patients receiving long-term antipsychotic treatment, metabolic syndrome components are not only highly prevalent but also actively worsen over time, with prevalence rates substantially exceeding both general population norms and many international studies. The concurrent and persistent gaps in the monitoring of blood pressure and glucose represent a serious patient safety issue and a major barrier to providing holistic, life-saving care. The findings from this study are a clear call to action. A paradigm shift is required, moving away from a siloed approach to mental health towards an integrated model of care. This requires systemic changes, including the implementation of mandatory, protocol-driven metabolic screening using checklists or electronic health record alerts, continuous training for all psychiatric staff on physical health monitoring, and fostering a collaborative culture between psychiatry, primary care, and endocrinology services. Only through such a concerted, multidisciplinary effort can we begin to close the unacceptable mortality gap faced by people with severe mental illness and ensure that the therapeutic benefits of antipsychotic medications are not overshadowed by preventable cardiometabolic complications.

1. Kang D, Lu J, Liu W, Shao P, Wu R. Association between olanzapine concentration and metabolic dysfunction in drug-naive and chronic patients: similarities and differences. Schizophrenia (Heidelb) [Internet]. 2022 [cited 2025 Sept 12];8(1):9. Available from: https://www.nature.com/articles/s41537-022-00211-5 2. Rans C. Olanzapine, clozapine show worst metabolic effects among antipsychotics [Internet]. Psychiatry Advisor. 2020 [cited 2025 Sept 12]. Available from: https://www.psychiatryadvisor.com/home/topics/schizophrenia-and-psychoses/olanzapine-clozapine-show-worst-metabolic-effects-among-antipsychotics/ 3. Yuen JWY, Kim DD, Procyshyn RM, Panenka WJ, Honer WG, Barr AM. A focused review of the metabolic side-effects of clozapine. Front Endocrinol (Lausanne) [Internet]. 2021;12:609240. Available from: http://dx.doi.org/10.3389/fendo.2021.609240 4. Yang Y, Chen B, Deng M, Song H, Yu M. The prevalence of frailty among patients with metabolic syndrome: a systematic review and meta-analysis. Contemp Nurse [Internet]. 2024;60(5):479–95. Available from: http://dx.doi.org/10.1080/10376178.2024.2360960 5. Kelebie M, Kibralew G, Tadesse G, Nakie G, Ali D, Fanta B, et al. Prevalence and predictors of metabolic syndrome among psychiatric patients receiving antipsychotic treatment in Africa: a systematic review and meta-analysis. BMC Psychiatry [Internet]. 2025;25(1):433. Available from: http://dx.doi.org/10.1186/s12888-025-06894-1 6. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med [Internet]. 2006;23(5):469–80. Available from: http://dx.doi.org/10.1111/j.1464-5491.2006.01858.x 7. Azfr Ali RS, Jalal Z, Paudyal V. Guidelines versus practice in screening and monitoring of cardiometabolic risks in patients taking antipsychotic medications: where do we stand? Gen Psychiatr [Internet]. 2021;34(4):e100561. Available from: http://dx.doi.org/10.1136/gpsych-2021-100561 8. Chang S-C, Goh KK, Lu M-L. Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives. World J Psychiatry [Internet]. 2021;11(10):696–710. Available from: http://dx.doi.org/10.5498/wjp.v11.i10.696 9. Ali RA, Jalal Z, Johal J, Paudyal V. Guideline adherence for cardiometabolic monitoring of patients prescribed antipsychotic medications in primary care: a retrospective observational study. Int J Clin Pharm [Internet]. 2023;45(5):1241–51. Available from: http://dx.doi.org/10.1007/s11096-023-01642-5 10. Zhu L, Spence C, Yang JW, Ma GX. The IDF definition is better suited for screening metabolic syndrome and estimating risks of diabetes in Asian American adults: Evidence from NHANES 2011-2016. J Clin Med [Internet]. 2020;9(12):3871. Available from: http://dx.doi.org/10.3390/jcm9123871 11. Hussain T, Margoob MA, Shoib S, Shafat M, Chandel RK. Prevalence of metabolic syndrome among psychiatric inpatients: A hospital based study from Kashmir. J Clin Diagn Res [Internet]. 2017;11(6):VC05–8. Available from: http://jcdr.net/article_fulltext.asp?issn=0973-709x&year=2017&volume=11&issue=6&page=VC05&issn=0973-709x&id=10011 12. Pandit K, Goswami S, Ghosh S, Mukhopadhyay P, Chowdhury S. Metabolic syndrome in South Asians. Indian J Endocrinol Metab [Internet]. 2012;16(1):44–55. Available from: http://dx.doi.org/10.4103/2230-8210.91187 13. Yuvaraj K, Sathish R, Sharan M, Tanveer R, Jayaprakash S, Sitanshu Sekhar K. Prevalence of metabolic syndrome among adult population in India: A systematic review and meta-analysis. PLoS One [Internet]. 2020;15(10):e0240971. Available from: http://dx.doi.org/10.1371/journal.pone.0240971 14. Al-Saati Y, Vijayakumar E, Khan E, Leong C, Hensel J, Kuzenko N. Metabolic monitoring among patients with psychotic disorders taking antipsychotics: results of a quality improvement project to address this challenging guideline-practice gap. BMJ Open Qual [Internet]. 2025;14(3):e003400. Available from: http://dx.doi.org/10.1136/bmjoq-2025-003400 15. Kumar D, Rajpoot A, Sachan P. Prevalence of metabolic syndrome in patients on long-term antipsychotic medication. Int J Life Sci Biotechnol Pharma Res [Internet]. 2024;13(8):539–45. Available from: https://www.ijlbpr.com/uploadfiles/93vol13issue8pp539-545.20240828102242.pdf 16. 18. Prasad DS, Kabir Z, Dash AK, Das BC. Prevalence and risk factors for metabolic syndrome in Asian Indians: A community study from urban Eastern India. J Cardiovasc Dis Res [Internet]. 2012;3(3):204–11. Available from: http://dx.doi.org/10.4103/0975-3583.98895 17. 19. Kumar GJ, Patnaik PK. Retrospective evaluation of antipsychotic-induced metabolic side effects in schizophrenia patients. Eur J Cardiovasc Med [Internet]. 2021 [cited 2025 Sept 12];11:69–72. Available from: https://healthcare-bulletin.co.uk/article/retrospective-evaluation-of-antipsychotic-induced-metabolic-side-effects-in-schizophrenia-patients-3077/ 18. 20. Shin S, Moon S, Wang J, Choi YJ. Impact of institutional quality improvement initiatives on metabolic monitoring in mental disorder in patients treated with antipsychotics: A meta-analysis of intervention studies. J Glob Health [Internet]. 2024;14(04074):04074. Available from: http://dx.doi.org/10.7189/jogh.14.04074